What is the drug of choice for uncomplicated adult urinary tract infection (cystitis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug of Choice for Uncomplicated Adult Urinary Tract Infection (Cystitis)

Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days is the preferred first-line treatment for uncomplicated cystitis in otherwise healthy adult women. 1, 2, 3

First-Line Treatment Options

  • Nitrofurantoin 100 mg twice daily for 5 days achieves clinical cure rates of 88–93% and bacteriologic cure rates of 81–92%, with minimal resistance (<10% globally) and limited collateral damage to normal flora. 1, 2, 3

  • Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg twice daily for 3 days is appropriate only when local E. coli resistance is documented to be <20% and the patient has not received this agent in the preceding 3–6 months. 1, 2

  • Fosfomycin trometamol 3 g as a single oral dose provides clinical cure rates of 90–91% but lower microbiologic cure rates (78–80%) compared to nitrofurantoin, making it a convenient alternative when multi-day regimens are problematic. 1, 2, 4

Critical Resistance Threshold for TMP-SMX

  • When E. coli is susceptible to TMP-SMX, clinical cure rates reach 90–100%; however, when the organism is resistant, cure rates plummet to 41–54%, making treatment failure the expected outcome. 1, 2

  • The 20% resistance threshold is derived from expert opinion integrating clinical outcomes, in-vitro data, and mathematical modeling; above this level, TMP-SMX should not be used empirically. 1, 2

Reserve (Second-Line) Agents

  • Fluoroquinolones (ciprofloxacin 250 mg twice daily for 3 days or levofloxacin) achieve bacteriologic eradication rates of 93–97% but should be reserved for pyelonephritis or when first-line agents are contraindicated, due to FDA warnings regarding tendon rupture, peripheral neuropathy, and aortic dissection. 1, 2, 5

  • Oral β-lactams (amoxicillin-clavulanate, cefdinir, cefaclor, cefpodoxime-proxetil) for 3–7 days demonstrate inferior efficacy and higher adverse-event rates compared to nitrofurantoin or TMP-SMX; they should be used only when first-line agents cannot be used. 1, 3

Agents to Avoid

  • Amoxicillin or ampicillin alone should never be used empirically because worldwide E. coli resistance exceeds 30%, resulting in poor therapeutic outcomes. 1, 3

Treatment Duration by Sex

  • Women: 3 days for TMP-SMX or 5 days for nitrofurantoin is sufficient for uncomplicated cystitis. 1, 2, 6

  • Men: 7 days of therapy is required for uncomplicated cystitis because short-course regimens that are effective in women are inadequate for men. 2

Contraindications to Nitrofurantoin

  • Suspected pyelonephritis (fever >38°C, flank pain, costovertebral angle tenderness, nausea/vomiting) is an absolute contraindication because nitrofurantoin does not achieve adequate renal tissue concentrations. 2, 3, 7

  • Creatinine clearance <30 mL/min contraindicates nitrofurantoin due to reduced efficacy and increased risk of peripheral neuropathy, pulmonary toxicity, and hepatotoxicity. 2, 7

Risk Factors Predicting TMP-SMX Resistance

  • Recent TMP-SMX exposure (within the preceding 3–6 months) independently predicts resistant infections and should prompt avoidance of empiric TMP-SMX. 2

  • Recent international travel (outside the United States within the preceding 3–6 months) is associated with higher rates of TMP-SMX-resistant uropathogens and similarly contraindicates empiric use. 2

Common Pitfalls to Avoid

  • Using nitrofurantoin for "borderline" upper-tract symptoms (e.g., mild flank pain or low-grade fever) is ineffective because the drug does not reach therapeutic concentrations in renal tissue. 2, 7

  • Prescribing TMP-SMX without local susceptibility data is discouraged, especially in regions where resistance exceeds the 20% threshold; hospital antibiograms often overestimate community resistance because they reflect complicated infections. 2

  • Empiric ciprofloxacin for simple cystitis contributes to rising resistance (now approximately 24% in many communities) and should be avoided unless resistance data specifically support its use. 2, 7

  • Treating asymptomatic bacteriuria in non-pregnant, non-catheterized patients promotes resistance without clinical benefit. 2, 3

Diagnostic Criteria

  • Diagnosis requires symptoms limited to dysuria, urgency, frequency, or suprapubic discomfort without fever, flank pain, nausea/vomiting, or costovertebral angle tenderness. 3, 7

  • Routine urine culture is not required for typical uncomplicated cystitis in otherwise healthy women; it should be reserved for atypical presentations, treatment failures, or recurrence within 2–4 weeks. 2, 3

Management of Treatment Failure

  • If symptoms have not resolved by day 3 of therapy or recur within 2 weeks, obtain a urine culture immediately and switch to a different antibiotic class for a full 7-day course. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Uncomplicated Urinary Tract Infection Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Cystitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Nitrofurantoin Dosing for Uncomplicated UTI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.